Department of Infectious Diseases, Shenzhen Luohu People's Hospital, The Third Affiliated Hospital, Shenzhen University, Shenzhen, Guangdong, China.
Department of Infectious Diseases, The Second Affiliated Hospital, Nanchang University, Nanchang, Jiangxi, China.
Gastroenterol Hepatol. 2022 May;45(5):361-372. doi: 10.1016/j.gastrohep.2021.10.001. Epub 2021 Oct 29.
This study aims to systematically review the performance of red blood cell distribution width to platelet ratio (RPR) in the diagnosis of significant or advanced fibrosis, and cirrhosis associated with hepatitis B virus (HBV).
The relevant studies were comprehensively searched in English databases such as Web of Science, PubMed, EMBASE, Cochrane Library, as well as Chinese databases such as China National Knowledge Infrastructure, Wanfang Data from the inception to March 2021. Accuracy of RPR in diagnosing significant or advanced fibrosis and liver cirrhosis was assessed by area under the curve (AUC), pooled sensitivity and specificity, as well as positive and negative likelihood ratios. Stata 15.0 software was applied to analyze the data.
In total, 13 literature met the requirements, including patients with significant fibrosis (n=1890), advanced fibrosis (n=645), and cirrhosis (n=499). The prevalence rates of significant fibrosis, advanced fibrosis and cirrhosis were 49.31% (range: 17.25-84.21%), 37.07% (range: 9.60-58.20%) and 2.18% (range: 2.78-44.19%), respectively. The AUCs for predicting significant fibrosis, advanced fibrosis, and cirrhosis by RPR were 0.73 (95%CI: 0.69-0.76), 0.80 (95%CI: 0.77-0.84) and 0.80 (95%CI: 0.76-0.83), respectively.
RPR is of some diagnostic value to the prediction of HBV-related significant fibrosis, advanced fibrosis and cirrhosis. This conclusion is urgently needed to be verified by further multi-center studies of large sample size and rigorous design.
本研究旨在系统评价红细胞分布宽度与血小板比值(RPR)在诊断乙型肝炎病毒(HBV)相关显著或晚期纤维化和肝硬化中的性能。
全面检索了 Web of Science、PubMed、EMBASE、Cochrane Library 等英文数据库和中国知网、万方数据等中文数据库,从建库至 2021 年 3 月收录的相关研究。采用曲线下面积(AUC)、汇总敏感度和特异度以及阳性和阴性似然比评估 RPR 诊断显著或晚期纤维化和肝硬化的准确性。采用 Stata 15.0 软件进行数据分析。
共纳入 13 项文献,包含显著纤维化(n=1890)、晚期纤维化(n=645)和肝硬化(n=499)患者。显著纤维化、晚期纤维化和肝硬化的患病率分别为 49.31%(范围:17.25%-84.21%)、37.07%(范围:9.60%-58.20%)和 2.18%(范围:2.78%-44.19%)。RPR 预测显著纤维化、晚期纤维化和肝硬化的 AUC 分别为 0.73(95%CI:0.69-0.76)、0.80(95%CI:0.77-0.84)和 0.80(95%CI:0.76-0.83)。
RPR 对预测 HBV 相关显著纤维化、晚期纤维化和肝硬化具有一定的诊断价值。但该结论还需进一步开展多中心、大样本、设计严谨的研究加以验证。